Q-omics provides the consensus-scored IL5 profile across patient tissues and cancer cell-line models. IL5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, IL5 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, IL5 RNA expression shows 16,293 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, COAD, and THYM as cancer lineages where IL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL5 survival associations across molecular data types. IL5 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL5 RNA expression–survival associations across cancer types. High IL5 expression shows unfavorable associations in THCA, CHOL, MESO and BRCA, but favorable associations in KIRP and THYM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify THCA as the clearest survival context for IL5 RNA expression.
This table summarizes IL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL5 shows lower tumor expression in LUAD, UCEC and LUSC and higher tumor expression in COAD, KIRC and CHOL. The COAD box plot shows higher IL5 RNA expression in tumor versus normal tissue (log2 FC = +0.062, t-test p = .012).
This table shows molecular features associated with IL5 in patient tissues and cancer cell lines. In patient samples, IL5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
